Introduction: Eptacog beta is a new recombinant activated human factor VII bypass- ing agent...
Read More
Predicting individual effects of switching from standard half-life (SHL) to extended half-life (EHL) FVIII/FIX...
Introduction: The phase 2/3 PROTECT VIII main study demonstrated efficacy and safety of BAY 94-9027...
Detection and analysis of blood donors seropositive for syphilis Background:The increasing incidence of syphilis...
Regular prophylaxis with exogenous factor VIII (FVIII) is recommended for individuals with severe haemophilia...
Introduction: Treatment optimization in haemophilia A can be achieved by choice of FVIII product...
The performance of surgery and invasive procedures in patients with haemophilia is currently facing new...
Hepatitis E virus (HEV) is the major cause of acute viral hepatitis in several...
Against a background of a rapidly evolving treatment landscape, a contemporary, evidence-based consolidated understanding...
The authors propose practical guidance for the diagnosis and management of COVID-19 coagulopathy in...